CELC Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and events related to CELC stock, including its financial results for 2025 where it reported a narrower loss and a net loss of $177 million. It also highlights the company's progress with the FDA for gedatolisib and its expected cash position to finance operations through 2027. Additionally, it covers market events, such as the U.S.-Iran negotiation outlook and its impact on various stocks.
Celcuity (CELC) 10K Form and Latest SEC Filings 2026
This article provides an overview of Celcuity's (CELC) latest SEC filings, highlighting that the company has submitted over 293 documents since 2017. It details the most recent filings, including a Form DEFA14A on April 2, 2026, a Form 4 for ownership change on January 9, 2026, an 8-K on March 25, 2026, and its 10-K annual report on March 26, 2026. The piece also explains the significance of various SEC filing types like 10-K, 10-Q, 8-K, and Form 4 for investors.
Richard Buller Sells 3,000 Shares of Celcuity (NASDAQ:CELC) Stock
Richard Buller, a director at Celcuity (NASDAQ:CELC), sold 3,000 shares of the company's stock on March 31, 2026, for $330,810, reducing his stake by over 30%. The transaction occurred under a pre-arranged Rule 10b5-1 plan. Celcuity's stock traded around $112.63, with analysts giving it a "Moderate Buy" rating and an average price target of $109.88.
Is It Too Late To Consider Celcuity (CELC) After Its Strong Multi‑Year Share Price Run?
This article analyzes Celcuity (CELC) stock after its significant multi-year price run, exploring whether it still offers value. Using discounted cash flow (DCF) analysis, the company appears undervalued, while its price-to-book (P/B) ratio suggests it's "about right" compared to its industry. The piece also presents "bull" and "bear" narratives with corresponding fair value estimates to help investors assess potential future performance.
Did Gedatolisib’s Priority Review and Commercial Build-Out Just Shift Celcuity's (CELC) Investment Narrative?
Celcuity reported widening net losses for 2025 but highlighted the FDA's priority review of its gedatolisib New Drug Application with a July 17, 2026 PDUFA date. The company is also progressing with its commercial build-out, aiming to shift its investment narrative from a purely loss-making entity to one with potential product revenue. Investors are encouraged to consider the balance between regulatory promise and the pressure of expanding net losses.
Hennion & Walsh Asset Management Inc. Acquires 19,579 Shares of Celcuity, Inc. $CELC
Hennion & Walsh Asset Management Inc. increased its stake in Celcuity, Inc. by 11.4% during the fourth quarter, purchasing an additional 19,579 shares to hold a total of 190,933 shares valued at approximately $19.04 million. Institutional investors now own 63.33% of the company, and Celcuity maintains a "Moderate Buy" consensus rating from analysts with a target price of $109.88. Director David Dalvey also sold 20,000 shares, decreasing his holdings by 18.18%.
Tudor Investment Corp ET AL Invests $1.35 Million in Celcuity, Inc. $CELC
Tudor Investment Corp ET AL has invested $1.35 million in Celcuity, Inc. (NASDAQ:CELC) by purchasing 27,340 shares, representing about 0.06% of the company. This comes as other hedge funds have also adjusted their holdings in Celcuity. The company's stock shows a "Moderate Buy" consensus from analysts with an average price target of $109.88, despite a recent insider sale by Director David Dalvey.
Assessing Celcuity (CELC) Valuation After FDA Priority Review And Commercial Launch Preparations
Celcuity (CELC) is undergoing valuation assessment following FDA priority review for its drug, gedatolisib, and accelerated commercial preparations. Despite recent short-term share price volatility, the long-term momentum has been strong. The company is currently loss-making but has a "most popular narrative" suggesting it is 9.2% undervalued with a fair value of $116.70, driven by a large addressable market and potential peak revenues for gedatolisib.
Assessing Celcuity (CELC) Valuation After FDA Priority Review And Commercial Launch Preparations
Celcuity (CELC) is under investor scrutiny following FDA priority review for gedatolisib and preparations for commercial launch. While the company is currently loss-making, its narrative suggests a significant undervaluation with a fair value of $116.70, driven by a projected $2.5b-$3b peak revenue for gedatolisib and an addressable market of $5b-$6b. However, a high P/B ratio compared to industry peers indicates that a lot of future growth may already be priced into the stock.
Celcuity Inc. (NASDAQ:CELC) Q4 2025 earnings call transcript
This document is a transcript of Celcuity Inc.'s Q4 2025 earnings call. It provides a detailed record of the company's financial results and discussions from the call, which can be valuable for investors and analysts. No specific financial details are provided in this brief entry.
Liquidity Mapping Around (CELC) Price Events
This article from Stock Traders Daily provides a liquidity mapping analysis for Celcuity Inc. (NASDAQ: CELC), highlighting a positive near-term sentiment that may impact a mid-term weak bias within a long-term strength context. It details AI-generated insights including support and resistance levels, and outlines three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored for different risk profiles. The analysis points to elevated downside risk due to the absence of additional long-term support signals.
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $125
LifeSci Capital has reiterated its Buy rating for Celcuity (CELC.US) and maintained a target price of $125. This indicates continued confidence in the company's prospects by the investment firm.
Celcuity (NASDAQ:CELC) Upgraded to Hold at Wall Street Zen
Celcuity (NASDAQ:CELC) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen. The company reported quarterly EPS of ($0.97), surpassing analyst estimates of ($1.06). The stock opened at $106.02, with a market cap of $4.91 billion, and has a consensus target price of $109.88 from ten analysts.
Celcuity’s Priority Review Puts Gedatolisib And Investor Trade Offs In Focus
Celcuity Inc. received FDA Priority Review for its New Drug Application for gedatolisib, a drug targeting advanced breast cancer, based on strong Phase 3 efficacy results. While this review and upcoming Phase 3 data for a specific cohort present significant market opportunities, the company is currently operating at a loss, highlighting a classic biotech trade-off between substantial upside potential and ongoing financial risk. Investors are advised to closely monitor the FDA's decision, upcoming trial data, and commercialization plans.
Celcuity Inc. (NASDAQ:CELC) Q4 2025 Earnings Call Transcript
Celcuity Inc. (NASDAQ:CELC) discussed its Q4 and full-year 2025 financial results and business updates, highlighting significant progress towards the potential FDA approval and commercialization of gedatolisib for HR-positive/HER2-negative advanced breast cancer. The company emphasized strong efficacy data from the PIK3CA wild-type cohort of the VIKTORIA-1 trial, which received priority review, and is preparing for the release of PIK3CA mutant cohort results in Q2 2026. Celcuity projects a total addressable market of over $5 billion for gedatolisib in the second-line setting, with potential peak annual revenue of up to $2.5 billion.
H.C. Wainwright reiterates Celcuity stock rating at neutral
H.C. Wainwright has reiterated a Neutral rating for Celcuity Inc (NASDAQ:CELC) with a $94 price target, despite the current market valuation being higher at $114.81. The firm highlighted an asymmetric risk profile due to potential data weaknesses from an upcoming mutant readout in Q2 2026. This comes as two other firms, Craig-Hallum and Stifel, recently raised their price targets for Celcuity and maintained Buy ratings.
Celcuity’s Priority Review Puts Gedatolisib And Investor Trade Offs In Focus
Celcuity received FDA Priority Review for its New Drug Application for gedatolisib in advanced breast cancer, following strong Phase 3 efficacy results. This review status and upcoming Phase 3 data for the PIK3CA mutant cohort intensely focus investor attention on Celcuity. Despite significant market opportunity, the company currently faces substantial losses and execution risks associated with late-stage trials and commercial launch preparations.
Why Celcuity Stock Popped Today
Celcuity's stock surged over 4% after the clinical-stage biotech released its 2025 financial results, reporting a significantly narrower-than-expected net loss for the fourth quarter. The company also announced a much stronger cash position, with nearly $166 million in cash and equivalents, providing a longer runway for its pure research and development phase. Investors are also anticipating topline results from a phase 3 clinical trial of gedatolisib for advanced breast cancer in the second quarter.
Stifel Raises Price Target for Celcuity (CELC) to $125, Maintains Buy Rating | CELC Stock News
Stifel analyst Stephen Willey has increased the price target for Celcuity (CELC) to $125 from $115, while reaffirming a "Buy" rating. This adjustment reflects an optimistic outlook for the company's stock, which aligns with an overall "Outperform" consensus from 11 brokerage firms. Celcuity, a clinical-stage biotechnology company, is currently focused on developing gedatolisib for oncology, with a Phase 3 clinical trial underway for advanced breast cancer.
Craig-Hallum raises Celcuity stock price target to $141 on NDA progress
Craig-Hallum has increased its price target for Celcuity Inc (NASDAQ:CELC) to $141 from $108, maintaining a Buy rating due to the company's progress across its pipeline and the accepted NDA for geda. The analyst cited confidence in the company's filing, especially regarding the practice-changing data for geda in wild-type populations. Additionally, Celcuity reported a strong Q4 2025 earnings surprise, and Stifel also raised its price target for the stock, anticipating topline data disclosure for a key clinical trial in Q2 2026.
Stifel raises Celcuity stock price target to $125 on trial timing
Stifel has increased its price target for Celcuity Inc (NASDAQ:CELC) shares to $125 from $115, maintaining a Buy rating. This adjustment follows refined guidance from Celcuity regarding topline data disclosure for a Phase 3 trial and reduced fiscal operating expense estimates. The company has shown significant stock performance, a Strong Buy consensus, and recently exceeded Q4 2025 earnings expectations.
Celcuity 10-K: $0 Revenue, $(3.79) EPS; $177M Net Loss
Celcuity (CELC) reported zero revenue for the year, alongside a net loss of $177.0 million, or $(3.79) per share, as detailed in its 10-K filing. The company's significant loss from operations, totaling $(172.2) million, was attributed to elevated R&D and G&A expenses, as it has yet to generate product sales. Despite the financial losses, Celcuity highlighted progress in clinical trials, regulatory approvals, and commercial readiness for potential future product launches.
Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations
Celcuity is projecting a potential $2.5 billion in annual peak revenue for its drug gedatolisib. This projection comes as the company approaches pivotal clinical milestones and prepares for the drug's commercial launch. This indicates significant market expectations for gedatolisib's performance.
Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations
Celcuity anticipates gedatolisib could achieve $2.5 billion in annual peak revenue, driven by upcoming pivotal clinical trials and strategic preparations for its commercial launch. The company is focusing on advancing milestones to bring this promising drug to market.
TD Cowen Maintains Celcuity(CELC.US) With Buy Rating
TD Cowen has reiterated its Buy rating on Celcuity (CELC.US). This indicates a continued positive outlook from the firm regarding Celcuity's stock performance.
Celcuity Inc reports results for the quarter ended December 31 - Earnings Summary
Celcuity Inc has reported its earnings results for the quarter that ended on December 31. This summary provides key financial information for the period. The report was published by Refinitiv and is available for further details.
Earnings call transcript: Celcuity beats Q4 2025 EPS forecast, stock rises
Celcuity Inc. (CELC) reported a better-than-expected EPS of -$0.73 for Q4 2025, significantly surpassing the forecast of -$1.05 and causing its stock to rise by 2.93% in aftermarket trading. The company's strategic investments in commercialization and a strong cash position are highlighted, along with progress in clinical trials for gedatolisib in breast and prostate cancer. Executives discussed plans for potential FDA approval of gedatolisib in 2026, aiming for a new standard of care in HR-positive, HER2-negative advanced breast cancer and outlining market potential.
CELCUITY ($CELC) Releases Q4 2025 Earnings
CELCUITY ($CELC) reported its Q4 2025 earnings, posting a loss of -$0.97 per share, which beat analyst estimates. The company also announced $0 in revenue. The article additionally details recent insider trading activity, institutional investor movements, analyst ratings, and price targets for CELC.
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Celcuity Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, alongside significant corporate updates. The FDA accepted Celcuity’s New Drug Application for gedatolisib, granting Priority Review with a PDUFA goal date of July 17, 2026, for advanced breast cancer. The company anticipates releasing topline results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 study in Q2 2026 and expects a transformative year with potential commercial launch of gedatolisib following FDA approval.
Celcuity (CELC) Projected to Post Earnings on Monday
Celcuity (NASDAQ:CELC) is expected to announce its Q4 2025 earnings before the market opens on Monday, March 30th, with analysts projecting a loss of ($1.06) per share. The stock has been trading down, and director David Dalvey recently sold a significant portion of his shares. Analysts currently rate Celcuity as a "Moderate Buy" with a consensus price target of $108.63.
Assessing Celcuity (CELC) Valuation After VIKTORIA-1 Data And New Analyst Buy Rating
Celcuity (CELC) is gaining investor attention following the publication of its Phase 3 VIKTORIA-1 data for its breast cancer drug candidate and a new analyst buy rating. While one analyst targets $190, suggesting upside from its current price near $114, the company's valuation metrics, such as a P/B ratio of 45.1x, are significantly higher than industry averages, indicating considerable optimism already priced in. Celcuity is a pre-revenue company, with analysts forecasting substantial revenue by March 2029 and a 25.1% profit margin within three years.
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
Celcuity Inc. announced it will release its financial results for the fourth quarter and full year 2025 on Wednesday, March 25, 2026, after market close. Management will host a webcast and teleconference at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a corporate update. Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for oncology, with lead candidate gedatolisib currently in multiple ongoing clinical trials.
Celcuity (CELC) price target increased by 11.17% to 108.57
The price target for Celcuity (CELC) stock has been increased by 11.17%, reaching $108.57. This adjustment reflects an updated valuation for the company.
Assessing Celcuity (CELC) Valuation After VIKTORIA-1 Data And New Analyst Buy Rating
Celcuity (CELC) is gaining attention after publishing Phase 3 VIKTORIA-1 data and receiving a new analyst buy rating. Despite a significant one-year return, the stock is still considered undervalued by one analyst with a target of US$190 against its current price near US$114. However, with a P/B ratio much higher than industry averages, its valuation is debated, reflecting both optimism and caution among investors.
Assessing Celcuity (CELC) Valuation After VIKTORIA-1 Data And New Analyst Buy Rating
Celcuity (CELC) is gaining investor attention after publishing Phase 3 VIKTORIA-1 data for its breast cancer drug and receiving a new analyst buy rating. Despite a significant 1-year return, the stock trades at US$114, which is below one analyst's target of US$190, prompting questions about its future upside. Analysts project substantial revenue growth and a 25.1% profit margin by March 2029 for this pre-revenue company, estimating its fair value at $116.70, though its high P/B ratio compared to peers suggests considerable optimism is already factored in.
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company, announced it will release its fourth quarter and full year 2025 financial results on Wednesday, March 25, 2026, after market close. Management will host a webcast/teleconference at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a corporate update. Details for accessing the teleconference and live webcast are provided.
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and ...
Celcuity Inc., a clinical-stage biotechnology company, announced it will release its fourth quarter and full year 2025 financial results on Wednesday, March 25, 2026, after market close. Management will host a webcast/teleconference on the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The company is focused on developing targeted therapies for oncology, with its lead candidate gedatolisib currently in multiple clinical trials.
Needham & Company LLC Reiterates Buy Rating for Celcuity (NASDAQ:CELC)
Needham & Company LLC has reiterated a "Buy" rating for Celcuity (NASDAQ:CELC), setting a price target of $122.00, which suggests a potential upside of 6.18%. Other analysts have also issued "Buy" ratings, with the consensus price target for the company currently standing at $108.63. Celcuity, a clinical-stage biotechnology company, specializes in precision oncology diagnostics and has seen significant institutional investor activity in recent quarters.
Why (CELC) Price Action Is Critical for Tactical Trading
The article provides a tactical trading analysis for Celcuity Inc. (NASDAQ: CELC), highlighting weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis to guide traders on potential price movements and risk management. Key findings point to an exceptional short setup with a significant risk-reward ratio.
HighVista Strategies LLC Purchases New Position in Celcuity, Inc. $CELC
HighVista Strategies LLC has acquired a new stake in Celcuity, Inc. (NASDAQ:CELC), purchasing 13,680 shares valued at approximately $676,000 during the third quarter. Other institutional investors like Soleus Capital Management L.P., Vanguard Group Inc., Eventide Asset Management LLC, Saturn V Capital Management LP, and UBS Group AG also increased their holdings in CELC. The company has a "Moderate Buy" rating from analysts with an average target price of $108.63, and 63.33% of its stock is owned by hedge funds and institutional investors.
49,281 Shares in Celcuity, Inc. $CELC Purchased by Granahan Investment Management LLC
Granahan Investment Management LLC has acquired 49,281 shares of Celcuity, Inc. (NASDAQ:CELC) worth approximately $2,434,000 during the third quarter, representing a 0.11% ownership stake. This purchase is part of a trend of institutional investors making changes to their positions in the company. Celcuity, a clinical-stage biotechnology company, has received a "Moderate Buy" consensus rating from analysts with an average price target of $108.63.
Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Celcuity, Inc. (NASDAQ:CELC) has received a "Moderate Buy" consensus rating from ten research firms, with an average 12-month price target of $108.63. The company's shares opened at $114.22, and it holds a market capitalization of $5.28 billion. Insider activity includes a recent sale of 20,000 shares by Director David Dalvey.
90,000 Shares in Celcuity, Inc. $CELC Purchased by Boxer Capital Management LLC
Boxer Capital Management LLC recently purchased 90,000 shares of Celcuity, Inc. (NASDAQ:CELC) for approximately $4.45 million, making it their 18th largest holding and a 0.19% ownership stake in the company. Analysts have a "Moderate Buy" consensus rating for Celcuity, with an average price target of $108.63, although some firms like Jefferies and Wells Fargo have higher targets despite a "sell" rating from Weiss. Celcuity, a clinical-stage biotechnology company, specializes in precision oncology diagnostics and currently trades around $114.22 with institutional investors and insiders owning 63.33% and 15.77% of the stock, respectively.
Apis Capital Advisors LLC Acquires New Holdings in Celcuity, Inc. $CELC
Apis Capital Advisors LLC has acquired a new significant stake in Celcuity, Inc. (NASDAQ:CELC), purchasing 776,000 shares valued at approximately $38.3 million, making it their largest position. Other institutional investors have also adjusted their holdings in Celcuity. The company's stock is trading near its 52-week high, with analysts generally rating it a "Moderate Buy" with an average price target of $108.63.
Wolfe Research Maintains Outperform on Celcuity Inc (CELC) Mar 12, 2026
Wolfe Research has maintained an Outperform rating on Celcuity Inc (CELC) on March 12, 2026, without changing its price target. This decision was based on the assessment that Relay's update did not alter efficacy benchmarks, leaving the analyst's view intact. The market reaction was minimal, with CELC's stock moving only 0.07%, suggesting the update was largely anticipated by investors.
Celcuity’s Gedatolisib Advances With Pivotal Data And FDA Priority Review
Celcuity reported positive efficacy and safety results from its Phase 3 VIKTORIA-1 trial of gedatolisib for advanced breast cancer, leading to the FDA granting Priority Review for the drug's new drug application with a PDUFA date in July 2026. The trial data highlighted a significant reduction in the risk of disease progression or death, positioning gedatolisib as a promising treatment for HR positive, HER2 negative advanced breast cancer. While the company is pre-revenue and reliant on external funding, its multi-target PAM inhibition approach could differentiate it from other market players if approved.
Celcuity stock maintained at Outperform by Wolfe on efficacy outlook
Wolfe Research maintained an Outperform rating and an $110.00 price target on Celcuity Inc (NASDAQ:CELC) shares, despite the stock already trading above this target. The firm commented on Relay Therapeutics’ zovegalisib data, noting that while it reinforces dose convenience, it doesn't significantly expand the efficacy ceiling, believing Celcuity's upcoming pivotal readout could exceed these benchmarks. Celcuity has also received Priority Review for its New Drug Application for gedatolisib from the FDA, with a decision expected by July 17, 2026.
Celcuity Stock Pre-Market (-0.2%): Needham Raises Target on Strong Data Publication
Needham has raised its price target for Celcuity (CELC) due to the strong data publication. The article reports that Celcuity's stock is down 0.2% in pre-market trading.
Is Celcuity (CELC) Pricing Reflecting Its Sharp Rally And DCF-Heavy Discount?
This article analyzes Celcuity's (CELC) current stock price using Discounted Cash Flow (DCF) analysis and Price-to-Book (P/B) ratio to determine if it is undervalued. The DCF model suggests significant undervaluation at $548.56 per share compared to the current $117.10, indicating a 78.7% discount. While the P/B ratio is high relative to industry averages, the article introduces "Narratives" as a tool for investors to build personalized valuation models.
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
Celcuity Inc. announced the publication of efficacy and safety results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib in the Journal of Clinical Oncology. The study showed significant improvement in median progression-free survival for patients with HR+/HER2- advanced breast cancer who previously received a CDK4/6 inhibitor, with the gedatolisib triplet reducing risk of progression or death by 76%. The FDA has granted Priority Review for Celcuity’s New Drug Application for gedatolisib, with a goal date of July 17, 2026.
